scholarly journals Assessment of channeling bias among initiators of glucose-lowering drugs: A UK cohort study [Corrigendum]

2018 ◽  
Vol Volume 10 ◽  
pp. 1787-1788
Author(s):  
Mikkel Z Ankarfeldt ◽  
Brian L Thorsted ◽  
Rolf HH Groenwold ◽  
Erpur Adalsteinsson ◽  
M Sanni Ali ◽  
...  
Keyword(s):  
Cohort Study ◽  
Glucose Lowering ◽  
Channeling Bias

scholarly journals Assessment of channeling bias among initiators of glucose-lowering drugs: A UK cohort study

2017 ◽  
Vol Volume 9 ◽  
pp. 19-30 ◽  
Author(s):  
Mikkel Zöllner Ankarfeldt ◽  
Brian Larsen Thorsted ◽  
Rolf Groenwold ◽  
Erpur Adalsteinsson ◽  
M Sanni Ali ◽  
...  
Keyword(s):  
Cohort Study ◽  
Glucose Lowering ◽  
Channeling Bias

scholarly journals Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands

2021 ◽  
Author(s):  
Rick I. Meijer ◽  
Trynke Hoekstra ◽  
Niels C. Gritters van den Oever ◽  
Suat Simsek ◽  
Joop P. van den Bergh ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
Hospital Admission ◽  
Clinical Outcomes ◽  
Primary Outcome ◽  
Infectious Complications ◽  
Glucose Lowering ◽  
Diabetes Severity ◽  
Outcome Mortality

Abstract Purpose Inhibition of dipeptidyl peptidase (DPP-)4 could reduce coronavirus disease 2019 (COVID-19) severity by reducing inflammation and enhancing tissue repair beyond glucose lowering. We aimed to assess this in a prospective cohort study. Methods We studied in 565 patients with type 2 diabetes in the CovidPredict Clinical Course Cohort whether use of a DPP-4 inhibitor prior to hospital admission due to COVID-19 was associated with improved clinical outcomes. Using crude analyses and propensity score matching (on age, sex and BMI), 28 patients using a DPP-4 inhibitor were identified and compared to non-users. Results No differences were found in the primary outcome mortality (matched-analysis = odds-ratio: 0,94 [95% confidence interval: 0,69 – 1,28], p-value: 0,689) or any of the secondary outcomes (ICU admission, invasive ventilation, thrombotic events or infectious complications). Additional analyses comparing users of DPP-4 inhibitors with subgroups of non-users (subgroup 1: users of metformin and sulphonylurea; subgroup 2: users of any insulin combination), allowing to correct for diabetes severity, did not yield different results. Conclusions We conclude that outpatient use of a DPP-4 inhibitor does not affect the clinical outcomes of patients with type 2 diabetes who are hospitalized because of COVID-19 infection.

scholarly journals Effect of different methods for estimating persistence and adherence to new glucose-lowering drugs: results of an observational, inception cohort study in Portugal

2018 ◽  
Vol Volume 12 ◽  
pp. 1471-1482 ◽  
Author(s):  
Carla Torre ◽  
Jose Guerreiro ◽  
Patricia Longo ◽  
Joao Filipe Raposo ◽  
Hubert Leufkens ◽  
...  
Keyword(s):  
Cohort Study ◽  
Inception Cohort ◽  
Glucose Lowering

Early glycaemic control among patients with type 2 diabetes and initial glucose-lowering treatment: a 13-year population-based cohort study

2015 ◽  
Vol 17 (8) ◽  
pp. 771-780 ◽  
Author(s):  
R. W. Thomsen ◽  
L. M. Baggesen ◽  
E. Svensson ◽  
L. Pedersen ◽  
H. Nørrelund ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cohort Study ◽  
Glycaemic Control ◽  
Population Based ◽  
Glucose Lowering
Sign in / Sign up

Export Citation Format

Share Document